vTv Therapeutics Inc (VTVT)
23.63
-0.07
(-0.29%)
USD |
NASDAQ |
May 03, 16:00
23.70
+0.06
(+0.28%)
After-Hours: 20:00
vTv Therapeutics Cash from Financing (Quarterly): -0.282M for Dec. 31, 2023
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.282M |
| September 30, 2023 | 0.473M |
| June 30, 2023 | 0.00 |
| March 31, 2023 | 11.81M |
| December 31, 2022 | 3.667M |
| September 30, 2022 | 6.303M |
| June 30, 2022 | 5.04M |
| March 31, 2022 | -0.256M |
| December 31, 2021 | 0.266M |
| September 30, 2021 | 12.32M |
| June 30, 2021 | 6.384M |
| March 31, 2021 | 8.001M |
| December 31, 2020 | 6.132M |
| September 30, 2020 | 0.869M |
| June 30, 2020 | 8.28M |
| March 31, 2020 | 4.189M |
| December 31, 2019 | 5.285M |
| September 30, 2019 | 6.859M |
| June 30, 2019 | 2.00M |
| March 31, 2019 | 8.726M |
| Date | Value |
|---|---|
| December 31, 2018 | 3.786M |
| September 30, 2018 | 8.868M |
| June 30, 2018 | 3.958M |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 7.50M |
| December 31, 2016 | 11.87M |
| September 30, 2016 | -0.055M |
| June 30, 2016 | -0.024M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 104.44M |
| June 30, 2015 | 10.44M |
| March 31, 2015 | 8.762M |
| December 31, 2014 | 7.122M |
| September 30, 2014 | 4.963M |
| June 30, 2014 | 8.713M |
| March 31, 2014 | 10.12M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-0.282M
Minimum
Dec 2023
12.32M
Maximum
Sep 2021
4.597M
Average
5.04M
Median
Jun 2022
Cash from Financing (Quarterly) Benchmarks
| Altimmune Inc | 72.75M |
| Palatin Technologies Inc | 4.974M |
| Oragenics Inc | -0.1806M |
| Viking Therapeutics Inc | 606.04M |
| G1 Therapeutics Inc | 0.034M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -2.914M |
| Cash from Investing (Quarterly) | 4.404M |
| Free Cash Flow | -19.08M |
| Free Cash Flow Per Share (Quarterly) | -1.308 |
| Free Cash Flow Yield | -38.73% |